Conventional methods for detecting DNA mutations lack sensitivity and completeness. In addition, the poor quality of the DNA extracted from paraffin biopsies is responsible for 20% of unsuccessful analyses by next-generation sequencing (NGS) using the Amplicon method. We have developed a method to overcome these drawbacks and have applied it to better diagnosis of several cancers and improved theranostics.
The laboratory has developed a next-generation "One Shot" sequencing method based on 11 genes for the detection of mutations related to drugs with a Marketing Authorization (MA) in oncology (for multiple types of cancers).
The accuracy and depth of the analysis provides the ability to detect these mutations, even the rarest, in the circulating DNA of blood plasma.
This technology drastically improves theranostics in the area of oncology and improves the ability of the oncologists to diagnose the cancer and choose the therapeutic strategy.
APPLICATIONS AND MARKETS
Oncology - Theranostics:
European patent application submitted on April 11th, 2018
Business Development Manager
+33 6 31 10 21 21